CUREVAC

CureVac is a global biopharmaceutical company with more than 20 years of experience in developing the mRNA technology for medical purposes... With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is the world's first company to successfully harness mRNA for medical purposes-because we saw opportunities where others saw obstacles. Today, we're more than 700 passionate people strong, each one committed to using the clinical potential of our proprietary mRNA technology to provide tailored solutions for those with the greatest medical needs... As a leading global clinical-stage biopharmaceutical company, we strive to create transformative medicines to protect and improve people's lives. Fueled by our proprietary RNA technology platform combined with two decades of science and manufacturing excellence, we are dedicated to creating novel treatments that enable the body to make its own..

Also known as: CureVac AG, CureVac Belgium SA, CureVac Corporate Services GmbH, CureVac Inc., CureVac Manufacturing GmbH, CureVac N.V., CureVac RNA Printer GmbH, CureVac SE

Registration numbers: HRB 754041 (W)

VAT numbers: DE 221 393 632

Primary location: Tuebingen Germany